LPCN Lipocine Inc.
Financings ·
Lipocine Inc. filed a prospectus supplement on February 26, 2026 under its sales agreement with A.G.P./Alliance Global Partners. It had sold $10,615,576 of stock under the earlier registration.
We have not published a story on Lipocine yet. When there is news, it will appear here.
Lipocine Inc. is a biopharmaceutical company that uses a proprietary technology platform to develop products with effective oral delivery of previously difficult to deliver molecules. Its lead product, TLANDO, is an oral treatment for testosterone replacement therapy in adult males with a deficiency or absence of endogenous testosterone, comprised of testosterone undecanoate. The company has licensed TLANDO to Verity Pharmaceuticals for the United States and Canada, to SPC Korea Limited for South Korea, to Pharmalink for the Gulf Cooperation Council countries, and to Aché for Brazil. It retains development and commercialization rights for TLANDO outside those territories. Its clinical development pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2203 for essential tremor, LPCN 2101 for epilepsy and LPCN 2401 for improved body composition in obesity management. Its focus areas also include liver disease and hormone supplementation for men and women. The company expects to seek partnerships for assets including LPCN 1148, a novel prodrug of testosterone and testosterone laurate.
| Product or program | What it is | Stage |
|---|---|---|
| TLANDO | Oral testosterone undecanoate for testosterone replacement therapy in adult males | Licensed to commercial partners in several territories |
| LPCN 1111 (TLANDO XR) | Once-daily oral testosterone tridecanoate for testosterone replacement therapy | Licensed to Verity for the United States and Canada |
| LPCN 1154 | Oral candidate for postpartum depression | Clinical development pipeline candidate |
| LPCN 2201 | Oral candidate for major depressive disorder | Clinical development pipeline candidate |
| LPCN 2203 | Oral candidate for essential tremor | Clinical development pipeline candidate |
| LPCN 2101 | Oral candidate for epilepsy | Clinical development pipeline candidate |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.0 million | $11.2 million |
| Research and development | $8.6 million | $7.4 million |
| Net income (loss) | -$9.6 million | $8,352 |
| Cash from operations | -$9.8 million | -$1.2 million |
| Cash and equivalents | $5.2 million | $6.2 million |
| Short-term investments | $9.7 million | $15.4 million |
Our latest story on this, dated Feb 26, 2026: "Lipocine raises its at-the-market program to $50,000,000". The story links the filing or release it is based on. Read the story.
Lipocine Inc. trades under the ticker LPCN on NASDAQ.
Lipocine Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Lipocine Inc. is 1535955. Its filings are on SEC EDGAR.
8,244,253 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-04.
Our directory records Lipocine Inc. under United States.
Our directory classifies Lipocine Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lipocine Inc. is US53630X2036.
aibio.space lists Lipocine Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Lipocine Inc. is a biopharmaceutical company that uses a proprietary technology platform to develop products with effective oral delivery of previously difficult to deliver molecules. Its lead product, TLANDO, is an oral treatment for testosterone replacement therapy in adult males with a deficiency or absence of endogenous testosterone, comprised of testosterone undecanoate.
TLANDO: Oral testosterone undecanoate for testosterone replacement therapy in adult males Stage: Licensed to commercial partners in several territories.
LPCN 1111 (TLANDO XR): Once-daily oral testosterone tridecanoate for testosterone replacement therapy Stage: Licensed to Verity for the United States and Canada.
$2.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Lipocine Inc. reported a net loss of $9.6 million for the fiscal year ended Dec 31, 2025, and used $9.8 million of cash in operations, per its annual report to the SEC.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio